Evidence map›Paper›PMID 35193818›Full record

SynthesisJournal of infection and public health2022

Clinical characteristics and outcome of coronavirus disease 2019 infection in patients with solid organ transplants: A systematic review and meta-analysis.

Wen An, Qiuyang Wang, Tae-Eun Kim, Ju-Seop Kang

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of infection and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Predominantly defective CD8Journal of translational medicine · 2023
    Article
  9. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2023
    Article
  10. Article
  11. Article
  12. Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wen AnDepartment of Pharmacology & Clinical Pharmacology, College of Medicine, Hanyang University, Seoul, South Korea. Electronic address: anwen@hanyang.ac.kr.
Qiuyang WangDepartment of Central China Research Institute of Health, Xinxiang Medical University, Xinxiang, China. Electronic address: 202034@xxmu.edu.cn.
Tae-Eun KimDepartment of Clinical Pharmacology, Konkuk University Hospital, Seoul, South Korea. Electronic address: tekim@kuh.ac.kr.
Ju-Seop KangDepartment of Pharmacology & Clinical Pharmacology, College of Medicine, Hanyang University, Seoul, South Korea. Electronic address: jskang@hanyang.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough many studies have reported cases of COVID-19 infection in transplant recipients, most of them only involve a small number of patients and narrow geographic areas. This study aims to investigate the clinical characteristics, morbidity, severity, and mortality of COVID-19 infection among solid organ transplant (SOT) recipients by meta-analysis.

methodWe performed a literature search using the databases PubMed, Web of Science, and Google Scholar as of November 26, 2020. We included randomized controlled trials and cohort studies, excluding case reports and small case series (n < 10). The pooled incidence proportion and 95% confidence intervals (CI) were used to estimate the combined results of forty-seven studies were included for the meta-analysis. Heterogeneity was assessed using I

resultsThe morbidity rate of COVID-19 in SOT recipients was 2.10% [95% CI 1.35-3.01], and the proportion of severe infection was 22.46% [95% CI 15.74-29.90]. The mortality rate was 17.38% [95% CI 13.72-21.34]. In the analysis by transplanted organ, the proportion of patients with severe infection was highest in recipients of two or more transplants 48.85% [95% CI 11.88-86.38]. The mortality rate was highest in lung transplant recipients 25.12% [95% CI 16.94-34.00]. The most common symptoms of COVID-19 in SOT recipients were fever (73.39%), cough (58.90%), and respiratory symptoms (45.77%).

conclusionSOT was a risk factor for worse COVID-19 outcomes, although the morbidity of COVID-19 in SOT recipients was not markedly higher than the general population. These results may change when our understanding of the disease progress.

Indexed as

COVID-19Organ TransplantationTransplant RecipientsHumansMorbidityRisk FactorsSARS-CoV-2COVID-19Meta-analysisSolid organ transplantationSOT

Identifiers

PMID35193818
PMCPMC8857642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.